Next Science Ltd NXS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- A$0.22
- Day Range
- A$0.20–0.22
- 52-Week Range
- A$0.18–0.50
- Bid/Ask
- A$0.20 / A$0.23
- Market Cap
- A$58.43 Mil
- Volume/Avg
- 39,736 / 125,110
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.53
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- —
- Website
- https://www.nextscience.com
Comparables
Valuation
|
Metric
|
NXS
|
000403
|
300896
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 23.84 | 34.89 |
Price/Book Value | 5.52 | 2.38 | 10.21 |
Price/Sales | 1.53 | 6.56 | 26.50 |
Price/Cash Flow | — | 19.85 | 38.67 |
Price/Earnings
NXS
000403
300896
Financial Strength
|
Metric
|
NXS
|
000403
|
300896
|
|---|---|---|---|
Quick Ratio | 1.81 | 2.45 | 15.24 |
Current Ratio | 2.17 | 3.72 | 16.84 |
Interest Coverage | −32.05 | 749.08 | 1,119.23 |
Quick Ratio
NXS
000403
300896
Profitability
|
Metric
|
NXS
|
000403
|
300896
|
|---|---|---|---|
Return on Assets (Normalized) | −96.17% | 8.89% | 28.38% |
Return on Equity (Normalized) | −201.37% | 10.33% | 30.49% |
Return on Invested Capital (Normalized) | −137.83% | 8.96% | 28.94% |
Return on Assets
NXS
000403
300896
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Rfkpxwhkjf | Thbw | $87.2 Bil | |||
| Merck KGaA ADR
MKKGY
| Qwqjsnpbs | Bkcvdh | $75.7 Bil | |||
| Haleon PLC ADR
HLN
| Vrbnbfy | Ytsr | $47.3 Bil | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Hlfhwgrs | Hrs | $20.0 Bil | |||
| Viatris Inc
VTRS
| Hwvwfsmt | Zmph | $13.7 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Rwkdwntm | Clt | $13.4 Bil | |||
| Catalent Inc
CTLT
| Cfdpqqxyg | Tfsgmvn | $11.0 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Wzcxpgfcf | Zdjqmvn | $3.5 Bil | |||
| Perrigo Co PLC
PRGO
| Fywknsxm | Qnrvw | $3.4 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Chfzbpnjnl | Skrnf | $2.4 Bil |
United States